To demonstrate the clinical relevance of our findings, we showed that the DNA methylation at the −963 CpG site of GABRP was decreased in primary ovarian tumors of advanced stage, but not of early stage, compared with that of their paired normal tissues, strongly suggesting that hypomethylation at the −963 CpG site is a marker for an aggressive form of ovarian cancer. This evidence concerns the gene GABRP and ovarian cancer.